Business Description
Fusion Antibodies PLC
ISIN : GB00BDQZGK16
Share Class Description:
LSE:FAB: Ordinary SharesDescription
Fusion Antibodies PLC offers various antibody engineering services for all therapeutic and diagnostic antibody development stages. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 13.72 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -3.56 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -50.4 | |||||
| 3-Year EBITDA Growth Rate | -20.8 | |||||
| 3-Year EPS without NRI Growth Rate | 30.1 | |||||
| 3-Year FCF Growth Rate | 18.4 | |||||
| 3-Year Book Growth Rate | -53.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 57.01 | |||||
| 9-Day RSI | 54.63 | |||||
| 14-Day RSI | 54.04 | |||||
| 6-1 Month Momentum % | 7.89 | |||||
| 12-1 Month Momentum % | 18.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.25 | |||||
| Quick Ratio | 2.73 | |||||
| Cash Ratio | 1 | |||||
| Days Inventory | 102.71 | |||||
| Days Sales Outstanding | 112.75 | |||||
| Days Payable | 104.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -55 | |||||
| Shareholder Yield % | -27.28 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 20.2 | |||||
| Operating Margin % | -92.23 | |||||
| Net Margin % | -90.29 | |||||
| FCF Margin % | -64.93 | |||||
| ROE % | -113.35 | |||||
| ROA % | -81.27 | |||||
| ROIC % | -188.57 | |||||
| ROC (Joel Greenblatt) % | -221.72 | |||||
| ROCE % | -112.26 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.27 | |||||
| PB Ratio | 3.91 | |||||
| Price-to-Tangible-Book | 4.3 | |||||
| EV-to-EBIT | -2.25 | |||||
| EV-to-EBITDA | -2.47 | |||||
| EV-to-Forward-EBITDA | -3.58 | |||||
| EV-to-Revenue | 2.07 | |||||
| EV-to-Forward-Revenue | 1.86 | |||||
| EV-to-FCF | -3.14 | |||||
| Price-to-Net-Current-Asset-Value | 4.3 | |||||
| Price-to-Net-Cash | 4.3 | |||||
| Earnings Yield (Greenblatt) % | -44.47 | |||||
| FCF Yield % | -28.36 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Fusion Antibodies PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | 1.802 | ||
| EPS (TTM) (£) | -0.024 | ||
| Beta | 2.16 | ||
| Volatility % | 108.8 | ||
| 14-Day RSI | 54.04 | ||
| 14-Day ATR (£) | 0.003123 | ||
| 20-Day SMA (£) | 0.042163 | ||
| 12-1 Month Momentum % | 18.84 | ||
| 52-Week Range (£) | 0.028 - 0.095 | ||
| Shares Outstanding (Mil) | 95.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Fusion Antibodies PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Fusion Antibodies PLC Stock Events
| Event | Date | Price(£) | ||
|---|---|---|---|---|
| No Event Data | ||||
Fusion Antibodies PLC Frequently Asked Questions
What is Fusion Antibodies PLC(LSE:FAB)'s stock price today?
The current price of LSE:FAB is £0.04. The 52 week high of LSE:FAB is £0.10 and 52 week low is £0.03.
When is next earnings date of Fusion Antibodies PLC(LSE:FAB)?
The next earnings date of Fusion Antibodies PLC(LSE:FAB) is 2024-12-04 Est..
Does Fusion Antibodies PLC(LSE:FAB) pay dividends? If so, how much?
Fusion Antibodies PLC(LSE:FAB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers